Mirum Pharmaceuticals (MIRM) Change in Accured Expenses (2019 - 2026)

Mirum Pharmaceuticals has reported Change in Accured Expenses for 8 years, with the latest figure at $57.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 387.72% year-over-year to $57.2 million; the trailing twelve-month figure through Mar 2026 stood at $95.6 million (up 134.5% YoY), and the FY2025 full-year result was $50.1 million, up 24.29% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $57.2 million, up from $3.4 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $57.2 million in Q1 2026, with the low at -$8.1 million in Q1 2022.
• Average Change in Accured Expenses over 5 years is $10.9 million, with a median of $9.3 million recorded in 2024.
• Year-over-year, Change in Accured Expenses sank 146.84% in 2022 and jumped 250660.0% in 2023.
• Tracing MIRM's Change in Accured Expenses over 5 years: stood at -$5000.0 in 2022, then jumped by 250660.0% to $12.5 million in 2023, then decreased by 25.45% to $9.3 million in 2024, then plunged by 63.13% to $3.4 million in 2025, then jumped by 1562.62% to $57.2 million in 2026.
• The last three Change in Accured Expenses figures came in at $57.2 million (Q1 2026), $3.4 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.

Peer Comparison